Rockwell Medical (NASDAQ:RMTI) announced preliminary unaudited financial results for the fourth quarter and full-year 2025, signaling a successful operational turnaround following a year of heavy customer transition.
The healthcare company, a leading supplier of hemodialysis concentrates, saw its gross margin jump to 22% in the final quarter, a sharp increase from the 14% reported in the third quarter of 2025.
The company expects to report net sales of approximately $18.6 million for the fourth quarter, bringing full-year 2025 revenue to roughly $69.5 million.
This performance lands at the top end of the company’s previous guidance range of $65 million to $70 million, despite the year-long headwind caused by its largest customer, DaVita, transitioning to a different supplier.
A key highlight for investors was the company's liquidity position.
Rockwell expects to report positive cash flow from operations of $2.3 million for the fourth quarter—the second time it has reached this milestone in 2025.
As a result, its cash, cash equivalents, and available-for-sale investments rose to approximately $25 million by year-end.
The margin improvement to 22% was driven by the closure of its South Carolina manufacturing facility and a strategic shift toward higher-margin contracts.
In early January 2026, the company further solidified its outlook by extending a major product purchase agreement through the end of 2026, which included a favorable price increase.
As the company enters 2026, management is pivoting from "steady-state" maintenance to an aggressive growth strategy focused on home dialysis products and international market expansion.